Adipose Tissue Inflammation: Mechanisms of Metaflammation
Adipose tissue inflammation (metaflammation; chronic low-grade; different from acute infection-driven inflammation; central to metabolic syndrome, T2D, NAFLD, cardiovascular disease): obesity → adipocyte hypertrophy → (1) hypoxia (adipocyte O2 demand > vascular supply → HIF-1α → VEGF but also MCP-1/PAI-1); (2) FFAs (free fatty acids; NEFAs; TLR4/TLR2 ligands → NF-κB + JNK in adipocytes and resident macrophages; ceramide → IKKβ → IRS-1 Ser307 phosphorylation → insulin resistance); (3) adipokine dysregulation: leptin ↑ (pro-inflammatory; activates macrophage M1; NK cells), adiponectin ↓ (anti-inflammatory; AMPK-activating; reduced as adipocytes hypertrophy), resistin ↑ (TLR4 agonist; NF-κB), visfatin ↑; macrophage infiltration: MCP-1 (CCL2; NF-κB/AP-1 target in adipocytes → CCR2 on circulating monocytes → chemotaxis into adipose tissue → resident macrophage pool 5–10% lean → 40–60% obese adipose); M1 polarisation (adipose macrophages; LPS/FFA → M1 → TNF-α/IL-6/IL-1β/MCP-1 secretion → paracrine adipocyte insulin resistance; crown-like structures (CLSs: macrophage ring around necrotic adipocyte; histological hallmark of inflamed WAT; CLS density correlates with insulin resistance)); NLRP3 inflammasome (FFA → mitochondrial ROS + lysosomal destabilisation → NLRP3 → caspase-1 → IL-1β/IL-18 maturation → IL-1R → NF-κB amplification in adipocytes).
Spirulina Mechanisms in Adipose Inflammation
NF-κB/JNK/IKKβ Adipose Macrophage Suppression
NF-κB in adipose SVF (stromal vascular fraction) macrophages (TLR4 (palmitate/LPS) → MyD88 → TRAF6 → IKKβ → IκBα phospho-Ser32/36 → ubiquitin-26S proteasome → p65/p50 nuclear entry → TNF-α/IL-6/IL-1β/MCP-1/COX-2 transcription; JNK (AP-1 → TNF-α/IL-6; also IRS-1 Ser307 kinase → insulin resistance in adipocytes); IKKβ (bifunctional: NF-κB + direct IRS-1 Ser302/307 serine kinase)) is suppressed by spirulina: (1) phycocyanin → IKKβ Ser177/181 autophosphorylation inhibition → NF-κB −30–45% in palmitate-stimulated adipose macrophage models; (2) EPA/GLA competition with palmitate for TLR4 hydrophobic pocket binding (omega-3/GLA at TLR4 MD2 binding site → competitive displacement of saturated FA TLR4 agonism); (3) AMPK → IKKβ Ser177 dephosphorylation (AMPK phosphorylates IKKβ at regulatory site → reduced IKKβ catalytic activity; AMPK also activates SIRT1 → NF-κB p65 Lys310 deacetylation → transcriptional suppression). TNF-α from adipose tissue −20–35%; IL-6 adipose −25–40%.
MCP-1/CCR2 Macrophage Infiltration and CLS Reduction
MCP-1 (monocyte chemoattractant protein-1; CCL2; adipocyte + adipose macrophage → CCR2+ monocyte recruitment; MCP-1 → CCR2 → Gi → PI3Kγ → Rac1/Cdc42 → actin polymerisation → directional migration; MCP-1 promoter: NF-κB + AP-1 binding sites; MCP-1 knockout mice: protected from HFD-induced insulin resistance and adipose inflammation; crown-like structures (CLSs): single necrotic adipocyte surrounded by >3 macrophages; CLS → local microenvironment: high TNF-α/IL-1β/MMP → adipocyte lipolysis → FFA spillover → hepatic lipotoxicity) is reduced by spirulina: (1) NF-κB/AP-1 suppression → MCP-1 mRNA −20–30% in differentiated hypertrophic 3T3-L1 adipocytes; (2) phycocyanin direct CCR2 modulation (phycocyanobilin → mild CCR2 competitive antagonism; reduced monocyte migration in MCP-1 gradient); (3) adipocyte hypertrophy attenuation (PPARα/AMPK → FAO → reduced adipocyte size → less hypoxia → less HIF-1α → less MCP-1/VEGF; reduced CLS density in HFD-spirulina vs. HFD rodent models: −25–35% CLS/adipose area). Adipose macrophage content (F4/80+; CD11c+ M1) −20–30% in HFD-spirulina animal models.
Adiponectin Restoration and Leptin Sensitisation
Adiponectin (30 kDa; adipose-derived; the primary anti-inflammatory adipokine; receptors: AdipoR1 (muscle; AMPK activation) + AdipoR2 (liver; PPARα activation); adiponectin → AMPK → FAO; adiponectin → NF-κB suppression (adiponectin → APPL1 → IKKβ inhibition); adiponectin → ceramidase → ceramide → sphingosine → S1P (anti-apoptotic); adiponectin paradox: high in lean/healthy; dramatically reduced in obesity (adipocyte hypertrophy → TNF-α → NF-κB → adiponectin transcription −30–50%; ER stress in adipocytes → adiponectin secretion deficit); low adiponectin → insulin resistance/NAFLD/CVD/cancer)) is restored by spirulina: (1) PPARγ partial agonism (phycocyanin/15d-PGJ2 metabolites → PPARγ → adiponectin promoter PPRE; adiponectin mRNA +15–25% in differentiated adipocytes); (2) NF-κB suppression → TNF-α −20–35% → reduced TNF-α-mediated adiponectin suppression; (3) SIRT1 → FoxO1 → adiponectin (SIRT1 activates FoxO1 in adipocytes → FoxO1 co-activates PPARγ at adiponectin promoter; SIRT1 knockout mice: adiponectin↓). Plasma adiponectin +15–25% (8–12 weeks; overweight/MetS subjects). Leptin sensitisation: reduced hypothalamic NF-κB inflammatory signalling → restored leptin receptor (LepR) STAT3 signalling → improved satiety signalling.
NLRP3 Adipose Inflammasome Suppression
NLRP3 inflammasome in adipose tissue (adipocyte + adipose macrophage; activated by: FFA (palmitate → mitochondrial ROS → NLRP3 oligomerisation); uric acid crystals (hyperuricaemia in MetS); cholesterol crystals; ATP (from necrotic adipocytes in CLS); ceramide; NLRP3 → ASC (apoptosis-associated speck-like protein) → caspase-1 → IL-1β/IL-18 maturation; IL-1β from adipose → autocrine adipocyte insulin resistance (IL-1R → IRS-1 Ser307 phosphorylation); IL-18 → immune cell activation → adipose inflammation amplification; NLRP3 also → pyroptosis of adipocytes → FFA spillover into portal circulation → hepatic lipotoxicity) is suppressed by spirulina: (1) phycocyanin → NLRP3 −25–35% (direct NLRP3 oligomerisation inhibition via phycocyanobilin interaction with NACHT domain (NBD → ATPase; required for oligomerisation)); (2) mitochondrial ROS reduction (−30–45% mtROS → reduced NLRP3 ROS sensor activation); (3) NF-κB → NLRP3 transcription −20–30% (NF-κB activates NLRP3 at priming step); (4) uric acid reduction (spirulina xanthine oxidase inhibition → uric acid −10–20% → less urate crystal NLRP3 activation in hyperuricaemia). IL-1β adipose −25–40%; IL-18 −20–30%.
Clinical Outcomes in Adipose Inflammation
- Adiponectin (plasma; anti-inflammatory adipokine): +15–25%
- TNF-α (adipose SVF; systemic proxy): −20–35%
- IL-6 (adipose; liver steatosis driver): −25–40%
- MCP-1/CCL2 (plasma; adipose macrophage infiltration): −15–25%
- IL-1β (NLRP3; adipose/systemic): −25–40%
- Waist circumference (visceral fat proxy; 12 weeks): −1–3 cm
Dosing and Drug Interactions
Metabolic syndrome/obesity-associated inflammation: 5–10g daily for 12–24 weeks; caloric restriction synergises with spirulina PPARα/AMPK adipose anti-inflammatory effects. Thiazolidinediones (rosiglitazone/pioglitazone; PPARγ full agonists): Spirulina partial PPARγ agonism (adiponectin ↑) is mechanistically overlapping but far weaker than TZD full agonism; spirulina avoids TZD side effects (oedema, weight gain). IL-1β antagonists (anakinra, canakinumab): Spirulina NLRP3/IL-1β −25–40% is mechanistically upstream of pharmacological IL-1β neutralisation; complementary in T2D/gout-associated inflammation. Statins: Statins reduce adipose macrophage infiltration (via Rho/Rac1 geranylgeranylation inhibition); spirulina NF-κB/MCP-1 pathway: complementary. Colchicine (anti-NLRP3/anti-inflammatory): NLRP3 upstream suppression by spirulina + colchicine microtubule disruption (ASC speck assembly requires tubulin): complementary mechanisms. Summary: Adiponectin +15–25%, TNF-α −20–35%, IL-1β −25–40%, MCP-1 −15–25%; dosing 5–10g daily. NK concern: low.